A Phase 4 interventional study of bOPV and Pentabio in Healthy, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 1 Minute to 1 Day, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-08.
Sponsored by PT Bio Farma · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to assess protectivity following four doses of bOPV which given simultaneously with Pentabio® and 1 dose of IPV at the 4th visit
To describe serological response after four doses of bOPV with 1 dose of IPV. To describe the antibody status to polio 60 days after birth dose of bOPV To assess the safety of bOPV which given simultaneously with Pentabio® and 1 dose 1 dosde of IPV at the 4th visit
PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally. The subject received bOPV, Pentabio and IPV according to the study schedule.
Biological: bOPV · Biological: Pentabio · Biological: IPV
Number of subjects with anti polio titer ≥ 8 for type 1, 2 and type 3
Evaluate protectivity
Time frame: 30 days after the last vaccination
Percentage of infants with increasing antibody titer >= 4 times
Serological response after four doses of bOPV with 1 dose of IPV
Time frame: 30 days after the last vaccination
Percentage of infants with transition of seronegative to seropositive
Serological response after four doses of bOPV with 1 dose of IPV
Time frame: 30 days after the last vaccination
Geometric Mean Titer (GMT) after four doses of bOPV with 1 dose of IPV
Geometric Mean Titer (GMT) 30 days after the last vaccination
Time frame: 30 days after the last vaccination
Number and severity of systemic adverse events (AEs) after each dose of bOPV, which given simultaneously with Pentabio and 1 dose of IPV
Assess the safety of bOPV
Time frame: first 30 minutes, 24hour, 48hour, 72hour and 30 days after vaccination.
Number of serious adverse events (SAE) which occured during the study
Assess the safety of bOPV
Time frame: 30 days after the last vaccination
Ran from Jul 2016 to primary completion in Mar 2017, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Poliovirus Vaccine, Oral · Poliovirus Vaccine, Inactivated